{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:29:54Z","timestamp":1760099394619},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1016\/s0145-2126(03)00181-4","type":"journal-article","created":{"date-parts":[[2003,9,3]],"date-time":"2003-09-03T17:06:23Z","timestamp":1062608783000},"page":"49-52","source":"Crossref","is-referenced-by-count":5,"title":["Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study"],"prefix":"10.1016","volume":"28","author":[{"given":"Daniel A","family":"Vaena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Stender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantin T","family":"Yiannoutsos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Stoner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry D","family":"Cripe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/S0145-2126(03)00181-4_BIB1","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V90.8.2969","article-title":"Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy","volume":"90","author":"Estey","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/S0145-2126(03)00181-4_BIB2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.1997.15.1.44","article-title":"Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia","volume":"15","author":"Seiter","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/S0145-2126(03)00181-4_BIB3","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood.V81.5.1146.1146","article-title":"Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia","volume":"81","author":"Kantarjian","year":"1993","journal-title":"Blood"},{"issue":"5\u20136","key":"10.1016\/S0145-2126(03)00181-4_BIB4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/10428199809057611","article-title":"Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"31","author":"Beran","year":"1998","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/S0145-2126(03)00181-4_BIB5","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.1989.7.9.1268","article-title":"On the value of intensive remission\u2013induction chemotherapy in elderly patients of >65 years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group","volume":"7","author":"Lowenberg","year":"1989","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/S0145-2126(03)00181-4_BIB6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.1990.8.2.272","article-title":"Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly","volume":"8","author":"Tilly","year":"1990","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/S0145-2126(03)00181-4_BIB7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2141.1996.d01-1769.x","article-title":"Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost; principal report of the Medical Research Council\u2019s AML9 study, MRC leukaemia in Adults Working Party","volume":"94","author":"Rees","year":"1996","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/S0145-2126(03)00181-4_BIB8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/10428190109097715","article-title":"Intravenous bolus topotecan in patients with myelodysplastic syndrome","volume":"42","author":"Seiter","year":"2001","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/S0145-2126(03)00181-4_BIB9","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/1097-0142(20011015)92:8<1999::AID-CNCR1538>3.0.CO;2-B","article-title":"High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens","volume":"92","author":"Beran","year":"2001","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/S0145-2126(03)00181-4_BIB10","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood.V98.13.3575","article-title":"Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts","volume":"98","author":"Estey","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/S0145-2126(03)00181-4_BIB11","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","article-title":"Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"17","author":"Beran","year":"1999","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212603001814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212603001814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T09:51:00Z","timestamp":1585129860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212603001814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0145212603001814"],"URL":"https:\/\/doi.org\/10.1016\/s0145-2126(03)00181-4","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}